SynthesisItalian journal of pediatrics2012
Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions.
Synthesis in Italian journal of pediatrics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Pooled it
- Oxidative Stress in Non-alcoholic Fatty Liver Disease. An Updated Mini Review.Frontiers in medicine · 2021Review
- Changes in Liver Enzymes and Metabolic Profile in Adolescents with Fatty Liver following Exercise Interventions.Pediatric gastroenterology, hepatology & nutrition · 2021Article
- The impact of depression, self-esteem, and body image on sleep quality in patients with PCOS: a cross-sectional study.Sleep & breathing = Schlaf & Atmung · 2020Article
- Ursodeoxycholic acid in the prevention of gallstones in patients subjected to Roux-en-Y gastric bypass1.Acta cirurgica brasileira · 2019Article
- Metabolomic Salivary Signature of Pediatric Obesity Related Liver Disease and Metabolic Syndrome.Nutrients · 2019Article
- Resveratrol-loaded PLGA nanoparticles: enhanced stability, solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy.Royal Society open science · 2018Article
- Article
- Sarcopenia and non-alcoholic fatty liver disease: Is there a relationship? A systematic review.World journal of hepatology · 2017Article
- Herbal medicines and nonalcoholic fatty liver disease.World journal of gastroenterology · 2016Review
- Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future.World journal of hepatology · 2015Review
- Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.World journal of gastroenterology · 2014Review
- Pediatric non alcoholic fatty liver disease: more on novel treatment targets.BMC pediatrics · 2013Article
- More on current evidences on probiotics as a novel treatment for non-alcoholic Fatty liver disease.Hepatitis monthly · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epidemics of overweight and obesity has resulted in a significant increase of non alcoholic fatty liver disease (NAFLD), a potentially progressive condition. Currently, obesity related hepatopathy represents therefore the main cause of pediatric chronic liver disease. The first choice treatment at all ages is weight loss and/or lifestyle changes, however compliance is very poor and a pharmacological approach has become necessary. In the present article we present a systematic literature review focusing on established pediatric NALFD drugs (ursodeoxycholic acid, insulin sensitizers, and antioxidants) and on innovative therapeutic options as well.Regarding the former ones, a pediatric pilot study highlighted that ursodeoxycholic acid is not efficient on transaminases levels and bright liver. Similarly, a recent large scale, multicenter randomized clinical trial (TONIC study) showed that also insulin sensitizers and antioxidant vitamin E have scarce effects on serum transaminase levels. Among a large series of novel therapeutic approaches acting on recently proposed different pathomechanisms, probiotics seem hitherto the most interesting and reasonable option for their safety and tolerability. Toll-like receptors modifiers, Pentoxifylline, and Farnesoid X receptors agonists have been still poorly investigated, and will need further studies before becoming possible promising innovative therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.